Cytec Industries Inc.Download PDFPatent Trials and Appeals BoardOct 19, 202014136660 - (D) (P.T.A.B. Oct. 19, 2020) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 14/136,660 12/20/2013 Susie C. Martins 13036S-US-CIP 5615 8015 7590 10/19/2020 CYTEC INDUSTRIES INC. 1937 WEST MAIN STREET STAMFORD, CT 06902 EXAMINER JEONG, YOUNGSUL ART UNIT PAPER NUMBER 1772 NOTIFICATION DATE DELIVERY MODE 10/19/2020 ELECTRONIC Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es): Cheryle.Telesco@solvay.com StamfordPatent@solvay.com PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE ____________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________ Ex parte SUSIE C. MARTINS, DOUGLAS A. NAFIS, and ALAKANANDA BHATTACHARYYA Appeal 2020-000322 Application 14/136,660 Technology Center 1700 ____________ Before ROMULO H. DELMENDO, MICHAEL P. COLAIANNI, and MICHAEL G. MCMANUS, Administrative Patent Judges. DELMENDO, Administrative Patent Judge. DECISION ON APPEAL The Appellant1 appeals under 35 U.S.C. § 134(a) from the Primary Examiner’s final decision to reject claims 1, 6–13, 30, and 31.2,3 We have jurisdiction under 35 U.S.C. § 6(b). We affirm. 1 We use the word “Appellant” to refer to “applicant” as defined in 37 C.F.R. § 1.42—i.e., “UOP LLC” (Application Data Sheet filed December 20, 2013 at 5). The Appellant identifies “Cytec Industries Inc.” as the real party in interest (Substitute Appeal Brief filed May 23, 2019 (“Appeal Br.”) at 2). 2 See Appeal Br. 4–14; Reply Brief filed October 9, 2019 (“Reply Br.”) at 2–6; Final Office Action entered October 1, 2018 (“Final Act.”) at 2–12; Examiner’s Answer entered August 13, 2019 (“Ans.”) at 3–7, 10–17. 3 Claims 14 and 15 are objected to as depending from a rejected base claim but are indicated as reciting allowable subject matter (Ans. 8–10). Appeal 2020-000322 Application 14/136,660 2 I. BACKGROUND The subject matter on appeal relates to phosphonium-haloaluminate compounds, which are useful as catalysts in processes for alkylation of paraffins with olefins (Specification filed December 20, 2013 (“Spec.”) ¶ 2). Representative claim 1 is reproduced from the Claims Appendix to the Appeal Brief, as follows: 1. An asymmetric quaternary phosphonium ionic liquid compound according to Formula (I): wherein each of R1-R3 is the same and is chosen from a C3- C6 alkyl group; and R4 is chosen from a C4-C12 alkyl group, wherein the R4 alkyl group contains more carbon atoms than the R1, R2, and R3 alkyl groups; and wherein the asymmetric quaternary phosphonium ionic liquid compound according to Formula (I) provides a higher Research Octane Number (RON) than ammonium chloroaluminates when reacting olefins and isoparaffins to produce high octane alkylates under reaction operating conditions having a temperature from 20 °C to 70 °C. (Appeal Br. 15). Appeal 2020-000322 Application 14/136,660 3 II. REJECTION ON APPEAL Claims 1, 6–13, 30, and 31 stand rejected under 35 U.S.C. § 103 as unpatentable over Randolph et al.4 (“Randolph”), as evidenced by Elomari et al.5 (“Elomari”) (Ans. 3–7, 10–17; Final Act. 2–12). III. DISCUSSION 1. Grouping of Claims Unless separately argued pursuant to 37 C.F.R. § 41.37(c)(1)(iv), the rejected claims stand or fall with claim 1, which we select as representative. Skeletal arguments based merely on what a claim recites are not arguments for separate patentability that require our separate consideration. In re Lovin, 652 F.3d 1349, 1357 (Fed. Cir. 2011). 2. The Examiner’s Position The Examiner finds that Randolph describes an alkylation catalyst including a cation that may be a symmetric or asymmetric phosphonium cation and an anion that may be a halide of a Group IIIA metal including, e.g., AlCl3 (Ans. 3–4; Final Act. 8–9). According to the Examiner, Randolph “anticipate[s]” the R1–R4 limitations as recited in claim 1 (Ans. 4; Final Act. 9 (citing Titanium Metals Corp. v. Banner, 778 F.2d 775 (Fed. Cir. 1985)). The Examiner states that “[a]lthough Randolph does not specifically disclose the anion haloaluminate of Al2Cl7[–] as per applicant claim 1, it is known that ionic liquid comprising quaternary phosphonium cation and Al2Cl7[–] anion[ is] formed via reacting Lewis acid AlCl3 with a cation component in the ionic liquid as evidenced by Elomari” (Ans. 4; Final 4 US 2005/0059848 A1, published March 17, 2005. 5 US 2007/0142211 A1, published June 21, 2007. Appeal 2020-000322 Application 14/136,660 4 Act. 9) (emphases removed)). Regarding the Research Octane Number (RON) property recited in claim 1, the Examiner states that this property would necessarily follow from Randolph’s teachings (Ans. 5; Final Act. 10). As for the Appellant’s argument based on evidence of unexpected results, the Examiner emphasizes that Randolph discloses asymmetric phosphonium ionic liquid compounds that are substantially the same as those recited in claim 1, and, therefore, the argument based on the proffered evidence is unpersuasive (Ans. 16–17; Final Act. 6–7). 3. The Appellant’s Contentions The Appellant concedes that “the Office has identified three species of phosphonium cations in the broad disclosure of Randolph together with an anion component comprising AlCl3 which might be encompassed by present [c]laim 1” (Appeal Br. 4).6 The Appellant argues, however, that “the fact that a claimed species or subgenus is encompassed by a prior art genus is not sufficient by itself to establish a prima facie case of obviousness” (id. at 4–5 (citing In re Baird, 16 F.3d 380, 382 (Fed. Cir. 1994)). In the Appellant’s view, the Examiner’s rejection does not follow the steps for analyzing the broad prior art genus-narrow claimed subgenus-species as set forth in MPEP 6 In the Reply Brief, the Appellant argues belatedly that AlCl3 is mentioned in the context of mixtures of Bronsted acid and Lewis acid 5)—not an anion that is part of the ionic liquid 6) (Reply Br. 2). Therefore, the Appellant’s position in the Reply Brief that AlCl3 is not an anion contradicts the position set forth in the Appeal Brief (id.). Consequently, we conclude that the Appellant’s new argument in the Reply Brief has been waived. See 37 C.F.R. § 41.41(b)(2). Even if AlCl3 is, in fact, not an anion, Randolph teaches AlCl3 as a Lewis acid, which may be used in combination with an ionic liquid (Randolph ¶¶ 11, 16). Therefore, any error on the part of the Examiner in this regard is harmless. Appeal 2020-000322 Application 14/136,660 5 § 2144.08 (id. at 6). According to the Appellant, the choices of ionic liquids in Randolph include over 86,000 possibilities (id. at 7–8). The Appellant also argues that “the combined art fails to suggest which alkylation catalyst would be successful in solving the technical problem of having to refrigerate reactors when ionic liquids are utilized in the alkylation of paraffins with olefins” (id. at 9). The Appellant alleges that “based on Randolph’s teaching of six chemical classes of alkylation catalsyts [sic], and of over 86,000 alkylation catalysts based on ionic liquids alone, Randolph and Elomari . . . fail to provide a small number of alkylation catalysts that could be easily investigated without undue experimentation” (id.). As for Elomari, the Appellant argues that “the only specific class of ionic liquids disclosed in Elomari . . . is 1-alkyl-pyridinium chloroaluminates” (id.). The Appellant acknowledges that “while there is a single mention of phosphonium ionic liquids being suitable for Friedel- Crafts alkylation in [Elomari’s] Background of the Invention[,]” the reference “is silent as to the chemical structure of the phosphonium ionic liquids” (id.). Furthermore, the Appellant argues that “unexpected advantages are associated with the presently claimed asymmetric quarternary [sic] phosphonium chloroaluminates” (id. at 10). In support, the Appellant relies on Figures 4 and 5 (Drawings filed December 20, 2013) (id. at 10–14). 4. Opinion We have fully considered the Appellant’s arguments but find that they fail to identify reversible error in the Examiner’s rejection. In re Jung, 637 F.3d 1356, 1365 (Fed. Cir. 2011). Appeal 2020-000322 Application 14/136,660 6 Randolph describes an alkylation catalyst composition comprising an acid component and a polymer, wherein the acid component is selected from the group consisting of 1) a sulfuric acid, 2) a fluorosulfonic acid, 3) a perhaloalkylsulfonic acid, 4) an ionic liquid, 5) mixtures of Bronsted acids and Lewis acids, and 6) combination of any two or more thereof (Randolph ¶¶ 10–11). With respect to the ionic liquid 4), Randolph discloses that it comprises a cation and an anion, wherein the cation may be selected from the group consisting of four identified ions and combinations thereof, and the anion is selected from the group consisting of halides of: Group IIIA metals, copper, zinc, iron, phosphorus, and combinations thereof (id. ¶¶ 12– 14). One of the four identified cations is described as being a phosphonium cation having a structure, as follows: wherein R5, R6, and R7 are selected from saturated and unsaturated hydrocarbyl groups containing 1–7 carbon atoms, and R8 is also selected from saturated and unsaturated hydrocarbyl groups containing 1–7 carbon atoms (id.). In addition, Randolph teaches the inclusion of compounds such as AlCl3 (id. ¶ 16). As picking and choosing from Randolph’s disclosure would be required to arrive at the claimed compound, Randolph does not describe with sufficient specificity (e.g., exemplify) a catalyst composition containing a phosphonium cation species that falls within the broad genus of cations recited in claim 1 and AlCl3. Therefore, we disagree with the Examiner’s Appeal 2020-000322 Application 14/136,660 7 position that Randolph “anticipate[s]” the R1–R3 and R4 limitations as recited in claim 1 (Ans. 4; Final Act. 9). Atofina v. Great Lakes Chem. Corp., 441 F.3d 991, 999 (Fed. Cir. 2006) (“Titanium Metals stands for the proposition that an earlier species reference anticipates a later genus claim, not that an earlier genus anticipates a narrower species.”). The Examiner’s erroneous finding, however, was harmless to the overall obviousness analysis because Randolph would have reasonably suggested to a person having ordinary skill in the art a composition including: a phosphonium cation in which Randolph’s R5, R6, and R7 are each identically C3, C4, C5, or C6 alkyl and R8 is C4, C5, C6, or C7 where R8 has a greater number of carbon atoms than R5–R7; and AlCl3 (Randolph ¶¶ 14, 16). Thus, even if the Appellant is correct that Randolph’s disclosure encompasses 86,000 possibilities (Appeal Br. 7–8), such a number of possibilities—where each would reasonably be expected to provide comparable, successful results in terms of alkylation and product properties based on structural similarity and use in view of Randolph’s teachings—is not the same as that involved in Baird in which our reviewing court held that a “disclosure of millions of compounds does not render obvious a claim to three compounds, particularly when that disclosure indicates a preference leading away from the claimed compounds” (emphases added). Baird, 16 F.3d at 383. Rather, the mere fact “[t]hat the [reference] discloses a multitude of effective combinations does not render any particular formulation less obvious.” Merck, 874 F.2d at 807. See also In re Corkill, 771 F.2d 1496, 1500 (Fed. Cir. 1985) (upholding obviousness rejection of claims based on prior art teaching that “hydrated zeolites will work” in detergent Appeal 2020-000322 Application 14/136,660 8 formulations, even though “the inventors selected the zeolites of the claims from among ‘thousands’ of compounds”); In re Arkley, 455 F.2d 586, 587 (CCPA 1972) (plurality) (“picking and choosing may be entirely proper in the making of a [§] 103, obviousness rejection.”). As for the Al2Cl7– anion recited in claim 1, the Examiner finds that Elomari provides evidence that Al2Cl7– anion would be present when an ionic liquid contains AlCl3 (Ans. 12). In this regard, Elomari discloses that Al2Cl7– anion would form from AlCl3 in an ionic liquid in which pyridinium or imidazolium cations are most commonly used but other cations such as phosphonium cations may also be used (Elomari ¶ 4). Given these facts, we detect no error in the Examiner’s finding that when AlCl3 is included in Randolph, it would reasonably appear that Al2Cl7– anion would necessarily form. The Appellant does not direct us to any evidence to the contrary. As for the Appellant’s argument that “the combined art fails to suggest which alkylation catalyst would be successful in solving the technical problem of having to refrigerate reactors when ionic liquids are utilized in the alkylation of paraffins with olefins” (Appeal Br. 9), the Supreme Court of the United States stated that such an approach to obviousness is incorrect. KSR Int’l Co. Teleflex Inc., 550 U.S. 398, 420 (2007) (“The first error of the Court of Appeals in this case was to foreclose [an obviousness] reasoning by holding that . . . patent examiners should look only to the problem the patentee was trying to solve.”). “Under the correct analysis, any need or problem known in the field of endeavor at the time of invention and addressed by the [prior art] can provide a reason for combining the elements in the manner claimed.” Id. See also In re Kemps, Appeal 2020-000322 Application 14/136,660 9 97 F.3d 1427, 1430 (Fed. Cir. 1996) (the motivation or reason in the prior art need not be the same as that of the inventor). With respect to unexpected results, we agree with the Examiner’s assessment that the evidence is insufficient because Randolph teaches phosphonium cations that are substantially the same as that recited in claim 1 (Ans. 16–17). Randolph discloses only four possible classes of cations for the ionic liquid—one of which is a phosphonium cation (Randolph ¶ 12). The Appellant’s proffered data appear to be limited to a comparison of two compounds falling within the broad scope of claim 1—namely, tributylpentylphosphonium chloroaluminate (TBPP) and tributylhexylphosphonium chloroaluminate (TBHP), which provided a higher trimethylpentane (TMP)/dimethylhexane (DMH) ratio than butylpyridinium chloroaluminate (BPy) and l-butyl-3-methylimidazolium chloroaluminate (BMIM) (Appeal Br. 11–12 (relying on Figs. 4–5)). Therefore, the relied-upon comparative data do not include a direct comparison against the closest prior art, which discloses phosphonium cations. In re Baxter Travenol Labs., 952 F.2d 388, 392 (Fed. Cir. 1991) (“[W]hen unexpected results are used as evidence of nonobviousness, the results must be shown to be unexpected compared with the closest prior art . . . Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention.”). Moreover, the comparative data are not reasonably commensurate in scope with the broad scope of claim 1, which encompasses numerous variations or possible choices in terms of combinations for R1 through R4. See, e.g., In re Grasselli, 713 F.2d 731, 743 (Fed. Cir. 1983) (“With respect to appellants’ broad claims to a catalyst with ‘an alkali metal,’ the Appeal 2020-000322 Application 14/136,660 10 experiments detailed in Friedrich III, being limited to sodium only, are not commensurate in scope, and are, therefore, insufficient to rebut the prima facie case.”). Alternatively, claim 1 should have been narrowed to be commensurate in scope with the proffered showing. In re Harris, 409 F.3d 1339, 1344 (Fed. Cir. 2005). For these reasons, we sustain the rejection as maintained against claim 1. The same analysis applies to claims 6–15, for which the Appellant offers only a skeletal argument (Appeal Br. 5–6). Therefore, we uphold the rejection as to these claims for the same reasons discussed above. IV. CONCLUSION In summary: Claims Rejected 35 U.S.C. § Reference(s)/Basis Affirmed Reversed 1, 6–13, 30, 31 103 Randolph, Elomari 1, 6–13, 30, 31 No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a). AFFIRMED Copy with citationCopy as parenthetical citation